Sorry. You can not access the page.

The page pro.biontech.com is not accessible from your location. You have been redirected to our corporate website for more information and resources.

See our Annual Report for the year 2024 for detailed updates on our pipeline candidates.

Pipeline

Breakthrough technologies to revolutionize medicine

2 pan-tumor priority programs

Explore our priority programs

20+ phase 2 and phase 3 clinical trials in oncology

Explore mid- to late-stage clinical trials

€2.25 bn investment into R&D in 2024

Explore our diversified pipeline

Stay up to date

Sign up for our email alert for news on our growing pipeline